ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Protein > IL-13 R alpha 2 > IL2-HF2H3

FITC-Labeled Human IL-13 R alpha 2 Protein, His Tag

  • Synonym
    IL13RA2,CD213A2,CT19,IL-13R,IL13BP
  • Source
    FITC-Labeled Human IL-13 R alpha 2, His Tag (IL2-HF2H3) is expressed from human 293 cells (HEK293). It contains AA Asp 27 - Arg 343 (Accession # Q14627-1). It is the FITC labeled form of Human IL-13 R alpha 2, His Tag (IL2-H52H5).
    Predicted N-terminus: Asp 27
  • Molecular Characterization
    IL-13 R alpha 2 Structure

    This protein carries a polyhistidine tag at the C-terminus

    The protein has a calculated MW of 39.0 kDa. The protein migrates as 45-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Conjugate

    FITC

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 535 nm

  • Labeling
    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.
  • Protein Ratio
    The FITC to protein molar ratio is 1-3.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
IL-13 R alpha 2 SDS-PAGE

FITC-Labeled Human IL-13 R alpha 2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
 IL-13 R alpha 2 ELISA

Immobilized Human IL-13, His Tag (Cat. No. IL3-H52H4) at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human IL-13 R alpha 2, His Tag (Cat. No. IL2-HF2H3) with a linear range of 0.313-1.25 μg/mL (QC tested).

 IL-13 R alpha 2 ELISA

Immobilized Monoclonal Anti-IL-13 R alpha 2 Antibody, Mouse IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human IL-13 R alpha 2, His Tag (Cat. No. IL2-HF2H3) with a linear range of 0.078-0.313 μg/mL (QC tested).

  • Background
    Interleukin-13 receptor subunit alpha-2 is also known as IL13Rα2, IL13Ra2 cluster of differentiation 213A2, CD213A2, CT19, IL-13R, IL13BP, and is a membrane bound protein that in humans is encoded by the IL13RA2 gene. IL13Rα2 is closely related to IL13Rα1, a subunit of the interleukin-13 receptor complex. This protein binds IL13 with high affinity, but lacks any significant cytoplasmic domain, and does not appear to function as a signal mediator. It is, however able to regulate the effects of both IL13 and IL4, despite the fact it is unable to bind directly to the latter. It is also reported to play a role in the internalization of IL13. IL13Rα2 is a component of the cell surface receptors, however, the majority exists in intracellular pools and in soluble form, and thus plays an opposite role as a potent IL13 antagonist compared with IL13Rα1. It also functions as an inhibitor of IL4-dependent pathway probably through the physical interaction between the short intracellular domain of and cytoplasmic domain of IL13Rα2 and the IL4Rα chain. In spite of the failed STAT signaling function, IL13Rα2 dose induce TGF-beta production and fibrosis. Additionally, IL13Rα2has been reported to be abundantly and specifically overexpressed in glioblastoma multiforme.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 89,320

価格(JPY) : 610,400

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:6 Details
  • Latest Research Phase:Phase 1 Clinical

データシート&ドキュメンテーション

DMF請求
DMF (Drug Master File)

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone